放疗联合特瑞普利单抗和GM-CSF治疗鼻腔鼻窦腺样囊性癌1例并文献复习

doi:10.3760/cma.j.cn371439-20230208-00085

摘要/Abstract

摘要：

鼻腔鼻窦腺样囊性癌是一种生长缓慢但预后差、复发率高、易局部扩散和远处转移的恶性肿瘤。现报道1例多次复发后应用放疗联合特瑞普利单抗及粒细胞巨噬细胞集落刺激因子治疗后疗效良好的鼻窦腺样囊性癌病例，并文献复习，以期为该类患者的治疗提供帮助。

关键词: 癌, 腺样囊性, 鼻窦, 粒细胞巨噬细胞集落刺激因子

贺嘉慧, 胡钦勇. 放疗联合特瑞普利单抗和GM-CSF治疗鼻腔鼻窦腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 442-444.

图/表 3

参考文献 24

[1]	Singaraju M, Singaraju S, Patel S, et al. Adenoid cystic carcinoma: a case report and review of literature[J]. J Oral Maxillofac Pathol, 2022, 26(Suppl 1): S26-S29. DOI: 10.4103/jomfp.jomfp_458_20. doi: 10.4103/jomfp.jomfp_458_20
[2]	Yarbrough WG, Panaccione A, Chang MT, et al. Clinical and molecular insights into adenoid cystic carcinoma: neural crest-like stemness as a target[J]. Laryngoscope Investig Otolaryngol, 2016, 1(4): 60-77. DOI: 10.1002/lio2.22. doi: 10.1002/lio2.22 pmid: 28894804
[3]	Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results[J]. Laryngoscope, 2006, 116(6): 982-986. DOI: 10.1097/01.mlg.0000216900.03188.48. doi: 10.1097/01.mlg.0000216900.03188.48
[4]	Ko YH, Lee MA, Hong YS, et al. Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck[J]. Jpn J Clin Oncol, 2007, 37(11): 805-811. DOI: 10.1093/jjco/hym119. doi: 10.1093/jjco/hym119 pmid: 18057012
[5]	Hickman RE, Cawson RA, Duffy SW. The prognosis of specific types of salivary gland tumors[J]. Cancer, 1984, 54(8): 1620-1624. DOI: 10.1002/1097-0142(19841015)54:8<1620::aid-cncr2820540824>3.0.co;2-i. doi: 10.1002/1097-0142(19841015)54:8<1620::aid-cncr2820540824>3.0.co;2-i pmid: 6089994
[6]	Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—an update[J]. Oral Oncol, 2015, 51(7): 652-661. DOI: 10.1016/j.oraloncology.2015.04.005. doi: 10.1016/j.oraloncology.2015.04.005 pmid: 25943783
[7]	Bell D, Roberts D, Kies M, et al. Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications[J]. Cancer, 2010, 116(24): 5749-5756. DOI: 10.1002/cncr.25541. doi: 10.1002/cncr.25541 pmid: 20824717
[8]	吕淑杰, 关兵. 左侧鼻窦腺样囊性癌一例及文献复习[J]. 中国医学文摘(耳鼻咽喉科学), 2020, 35(3): 214-216, 148. DOI: 10.19617/j.issn1001-1307.2020.03.214. doi: 10.19617/j.issn1001-1307.2020.03.214
[9]	Ju WT, Zhao TC, Liu Y, et al. Computed tomographic features of adenoid cystic carcinoma in the palate[J]. Cancer Imaging, 2019, 19(1): 3. DOI: 10.1186/s40644-019-0190-z. doi: 10.1186/s40644-019-0190-z
[10]	Eggesbø HB. Imaging of sinonasal tumours[J]. Cancer Imaging, 2012, 12: 136-152. DOI: 10.1102/1470-7330.2012.0015. doi: 10.1102/1470-7330.2012.0015 pmid: 22571851
[11]	Lee YY, Wong KT, King AD, et al. Imaging of salivary gland tumours[J]. Eur J Radiol, 2008, 66(3): 419-436. DOI: 10.1016/j.ejrad.2008.01.027. doi: 10.1016/j.ejrad.2008.01.027 pmid: 18337041
[12]	Li Y, Hao D, Song X, et al. Computed tomography and magnetic resonance imaging of adenoid cystic carcinoma in the maxillary sinus: a retrospective study with radiologic-histopathologic correlations[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(1): 111-121. DOI: 10.1016/j.oooo.2020.06.019. doi: 10.1016/j.oooo.2020.06.019
[13]	Fang Y, Peng Z, Wang Y, et al. Current opinions on diagnosis and treatment of adenoid cystic carcinoma[J]. Oral Oncol, 2022, 130: 105945. DOI: 10.1016/j.oraloncology.2022.105945. doi: 10.1016/j.oraloncology.2022.105945
[14]	Balamucki CJ, Amdur RJ, Werning JW, et al. Adenoid cystic carcinoma of the head and neck[J]. Am J Otolaryngol, 2012, 33(5): 510-518. DOI: 10.1016/j.amjoto.2011.11.006. doi: 10.1016/j.amjoto.2011.11.006
[15]	Wardas P, Tymowski M, Piotrowska-Seweryn A, et al. Endoscopic approach to the resection of adenoid cystic carcinoma of paranasal sinuses and nasal cavity: case report and own experience[J]. Eur J Med Res, 2015, 20: 97. DOI: 10.1186/s40001-015-0189-2. doi: 10.1186/s40001-015-0189-2 pmid: 26653204
[16]	Wiseman SM, Popat SR, Rigual NR, et al. Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases[J]. Ear Nose Throat J, 2002, 81(8): 510-514, 516-517. doi: 10.1177/014556130208100810
[17]	Lupinetti AD, Roberts DB, Williams MD, et al. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience[J]. Cancer, 2007, 110(12): 2726-2731. DOI: 10.1002/cncr.23096. doi: 10.1002/cncr.23096 pmid: 17960615
[18]	Michel G, Joubert M, Delemazure AS, et al. Adenoid cystic carcinoma of the paranasal sinuses: retrospective series and review of the literature[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2013, 130(5): 257-262. DOI: 10.1016/j.anorl.2012.09.010. doi: 10.1016/j.anorl.2012.09.010 pmid: 23747147
[19]	Amit M, Binenbaum Y, Sharma K, et al. Adenoid cystic carcinoma of the nasal cavity and paranasal sinuses: a meta-analysis[J]. J Neurol Surg B Skull Base, 2013, 74(3): 118-125. DOI: 10.1055/s-0033-1347358. doi: 10.1055/s-0033-1347358
[20]	Husain Q, Kanumuri VV, Svider PF, et al. Sinonasal adenoid cystic carcinoma: systematic review of survival and treatment strategies[J]. Otolaryngol Head Neck Surg, 2013, 148(1): 29-39. DOI: 10.1177/0194599812464020. doi: 10.1177/0194599812464020
[21]	Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator[J]. Nature, 1985, 314(6009): 361-363. DOI: 10.1038/314361a0. doi: 10.1038/314361a0
[22]	Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial[J]. JAMA, 2014, 312(17): 1744-1753. DOI: 10.1001/jama.2014.13943. doi: 10.1001/jama.2014.13943 pmid: 25369488
[23]	Kong Y, Zhao X, Xu M, et al. PD-1 inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase Ⅱ study[J]. Front Immunol, 2022, 13: 952066. DOI: 10.3389/fimmu.2022.952066. doi: 10.3389/fimmu.2022.952066
[24]	Xu H, Hong Z, Xu M, et al. PRaG therapy of refractory metastatic gastric cancer: a case report[J]. Front Immunol, 2022, 13: 926740. DOI: 10.3389/fimmu.2022.926740. doi: 10.3389/fimmu.2022.926740

放疗联合特瑞普利单抗和GM-CSF治疗鼻腔鼻窦腺样囊性癌1例并文献复习

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.